加载中
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
收盘时
US$1.80
−US$0.04 · -2.17%
盘后
US$1.80
US$0.00 · 0.00%
10月12日 17:40 ET
盘中时间采用ET。市场数据可能有所延迟。
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
日内区间
当前US$1.80
52周区间
当前US$1.80
盘中时间采用ET。市场数据可能有所延迟。
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
日内区间
当前US$1.80
52周区间
当前US$1.80
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 9049.7万 USD | 8378.9万 USD | 6867.5万 USD | 5366.2万 USD | 4841.6万 USD |
| 销货成本 | 2335.8万 USD | 2178.8万 USD | 1792.3万 USD | 1379.7万 USD | 1278.6万 USD |
| 毛利 | 6713.9万 USD | 6200.1万 USD | 5075.2万 USD | 3986.5万 USD | 3563万 USD |
| 研究与开发 | 1949.1万 USD | 1757万 USD | 1808万 USD | 1539.7万 USD | 1306.3万 USD |
| 销售、一般及管理费用 | 1.01亿 USD | 1.02亿 USD | 9460.7万 USD | 8310.5万 USD | 6987.1万 USD |
| 营业费用 | 1.21亿 USD | 1.2亿 USD | 1.13亿 USD | 9850.2万 USD | 8293.4万 USD |
| 利息收入 | 265.1万 USD | 506.1万 USD | 556.8万 USD | 152.9万 USD | 40万 USD |
| 利息支出 | 315.5万 USD | 350.7万 USD | 323.2万 USD | 106.6万 USD | 82.9万 USD |
| 折旧和摊销 | 105.4万 USD | 149.3万 USD | 154.8万 USD | 151.3万 USD | 86.7万 USD |
| 营业利润 | −5366.3万 USD | −5770.4万 USD | −6193.5万 USD | −5863.7万 USD | −4730.4万 USD |
| 净利润 | −5400.3万 USD | −5639.4万 USD | −6084.3万 USD | −5892.3万 USD | −4866.1万 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$10.00
上涨空间 455.56%AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
